Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 403 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Locally Advanced Lung Non-Small Cell Carcinoma Clear all
Terminated Phase 1 Interventional

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

NCT02468661
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
INC280 single agent, erlotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Jul 23, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional Results available

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

NCT04372927
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Pemetrexed
Drug · Biological · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NCT05624996
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
476
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 2 Interventional

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT07489066
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
Interventions
PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Hinsdale, Illinois • New Lenox, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 1 Interventional

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

NCT04297605
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

NCT04424641
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
Interventions
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

NCT02352948
View directory record Official record
Conditions
Non - Small Cell Lung Cancer NSCLC
Interventions
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
33
States / cities
Chandler, Arizona • Anaheim, California • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

NCT07488676
View directory record Official record
Conditions
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions
ASP546C
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00003089
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Interventions
amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Results available

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

NCT02443324
View directory record Official record
Conditions
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer
Interventions
Ramucirumab, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Jul 23, 2026, 6:23 AM EDT
Terminated Phase 1 Interventional

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

NCT06364696
View directory record Official record
Conditions
Solid Tumor
Interventions
ASP4396
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Westwood, Kansas • Grand Rapids, Michigan • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380
View directory record Official record
Conditions
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions
tucatinib, trastuzumab, fulvestrant
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
75
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Not listed Phase 2 Interventional

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00278187
View directory record Official record
Conditions
Lung Cancer
Interventions
volociximab, erlotinib hydrochloride
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

NCT01362296
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
GSK1120212, docetaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
Scottsdale, Arizona • Orange, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery

NCT02262325
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
hypofractionated radiation therapy, cisplatin, etoposide, 3-dimensional conformal radiation therapy, laboratory biomarker analysis
Radiation · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

NCT04691817
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
Atezolizumab, Tocilizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 2 Interventional

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

NCT05692635
View directory record Official record
Conditions
Brain Metastases, Nonsmall Cell Lung Cancer Stage III
Interventions
MRI of the Brain, Blood draws, Quality of Life Questionnaires, Gadolinium
Diagnostic Test · Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Recruiting Phase 2 Interventional

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Rilvegostomig, Ramucirumab, Dato-DXd
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Santa Monica, California • Santa Rosa, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03071757
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-368, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
La Jolla, California • Sacramento, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Jul 23, 2026, 6:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Pembrolizumab, Dostarlimab, Belrestotug, Nelistotug
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Plantation, Florida • Albuquerque, New Mexico • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

NCT04225117
View directory record Official record
Conditions
Locally Advanced or Metastatic Malignant Solid Tumors
Interventions
enfortumab vedotin, pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Not applicable Interventional

Once Weekly Radiation for Lung Cancer With Chemotherapy

NCT00256789
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Radiation, Chemotherapy
Procedure · Drug
Lead sponsor
Clinical Oncology Research Associates
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Jul 23, 2026, 6:23 AM EDT